Headache · 2026
Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Falcão Luciano, Brenner Leonardo B O, Machado Magalhães Pedro Lucas, Goyal Abhishek, de Bastos Maximiano Mariana Leticia, Donato Kenzo Ogasawara, Silva Rafael Andrade Sampaio, Pereira Gonzalez Joao Victor, da Silva, Corin Anderson Silva, Zarroli Katherine
Аннотация
OBJECTIVES/BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for type 2 diabetes and obesity, have emerged as promising candidates for idiopathic intracranial hypertension (IIH) due to their metabolic and neurophysiological effects. This systematic review and meta-analysis aims to summarize, synthesize, and quantitatively pool the available evidence on the use of GLP-1 RAs in patients with IIH, focusing on clinical outcomes.
METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched through December 2025 for randomized trials and cohort studies assessing GLP-1 RAs in patients with IIH. Risk of bias was assessed by Risk of Bias in Nonrandomized Studies of Interventions and Cochrane Risk of Bias 2.0. Primary outcomes included papilledema, headache burden, refractory IIH, and visual disturbances.
RESULTS: Eight studies comprising 13,243 patients met inclusion criteria. GLP-1 RAs significantly reduced papilledema risk at 3 months (risk ratio [RR], 0.430; 95% confidence interval [CI], 0.281-0.659; I-squared statistic [I2] = 62.5%) and maintained the benefit through 24 months (RR, 0.469; 95% CI, 0.382-0.576; I2 = 18.0%). Headache frequency was also consistently lower at 3 months (RR, 0.690; 95% CI, 0.557-0.853; I2 = 71.0%) and at 24 months (RR, 0.796; 95% CI, 0.691-0.916; I2 = 68.9%), with similar improvements in visual disturbances at 3 months (RR, 0.408; 95% CI, 0.304-0.547; I2 = 36.0%) and 24 months (RR, 0.433; 95% CI, 0.236-0.796; I2 = 79.0%), and refractory IIH at 3 months (RR, 0.696; 95% CI, 0.574-0.843; I2 = 60.0%) and 24 months (RR, 0.808; 95% CI, 0.715-0.908; I2 = 52.0%) compared to control group.
CONCLUSION: GLP-1 RAs appear associated with improvements in clinical outcomes in IIH, including reductions in papilledema, headache, and visual symptoms. The current evidence base is dominated by observational studies with moderate to serious risk of confounding, resulting in low-certainty, hypothesis-generating evidence. These findings should be interpreted cautiously and primarily serve to inform the design of future well powered randomized controlled trials.
METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched through December 2025 for randomized trials and cohort studies assessing GLP-1 RAs in patients with IIH. Risk of bias was assessed by Risk of Bias in Nonrandomized Studies of Interventions and Cochrane Risk of Bias 2.0. Primary outcomes included papilledema, headache burden, refractory IIH, and visual disturbances.
RESULTS: Eight studies comprising 13,243 patients met inclusion criteria. GLP-1 RAs significantly reduced papilledema risk at 3 months (risk ratio [RR], 0.430; 95% confidence interval [CI], 0.281-0.659; I-squared statistic [I2] = 62.5%) and maintained the benefit through 24 months (RR, 0.469; 95% CI, 0.382-0.576; I2 = 18.0%). Headache frequency was also consistently lower at 3 months (RR, 0.690; 95% CI, 0.557-0.853; I2 = 71.0%) and at 24 months (RR, 0.796; 95% CI, 0.691-0.916; I2 = 68.9%), with similar improvements in visual disturbances at 3 months (RR, 0.408; 95% CI, 0.304-0.547; I2 = 36.0%) and 24 months (RR, 0.433; 95% CI, 0.236-0.796; I2 = 79.0%), and refractory IIH at 3 months (RR, 0.696; 95% CI, 0.574-0.843; I2 = 60.0%) and 24 months (RR, 0.808; 95% CI, 0.715-0.908; I2 = 52.0%) compared to control group.
CONCLUSION: GLP-1 RAs appear associated with improvements in clinical outcomes in IIH, including reductions in papilledema, headache, and visual symptoms. The current evidence base is dominated by observational studies with moderate to serious risk of confounding, resulting in low-certainty, hypothesis-generating evidence. These findings should be interpreted cautiously and primarily serve to inform the design of future well powered randomized controlled trials.